-
Honokiol Triggers Paraptosis in APL via mTOR and MAPK Activa
2026-05-14
This study demonstrates that honokiol induces caspase-independent, paraptosis-like cell death in acute promyelocytic leukemia (APL) cells by activating mTOR and MAPK pathways. The findings advance mechanistic understanding of non-apoptotic death in leukemia and offer new directions for overcoming apoptosis resistance in cancer treatment.
-
Imatinib Hydrochloride: Applied Protocols for Kinase Inhibit
2026-05-13
Imatinib hydrochloride (STI571 hydrochloride) offers precise, multi-target kinase inhibition for advanced cancer research workflows. Discover optimized protocols, troubleshooting strategies, and actionable insights leveraging APExBIO’s trusted compound for reproducible, high-sensitivity results.
-
Disrupting BRD4-RAC1 Signaling: Epigenetic Axes in Breast Ca
2026-05-13
This article examines a 2021 study introducing a dual-targeting strategy against BRD4 and RAC1 in breast cancer, revealing suppression of tumor growth and stemness via c-MYC-G9a-FTH1 axis disruption and HDAC1 downregulation. The findings highlight the mechanistic relevance of epigenetic modulation in controlling tumorigenesis across molecular subtypes, offering new directions for therapeutic research.
-
Azilsartan Medoxomil Monopotassium: Precision in Hypertensio
2026-05-12
Azilsartan medoxomil monopotassium (TAK 491) delivers unmatched selectivity and sustained receptor occupancy, making it a top-tier choice for essential hypertension treatment research and cardiovascular disease models. Streamline your blood pressure regulation studies with workflow-validated protocols, troubleshooting insights, and comparative data from leading ARB compounds.
-
Pazopanib (GW-786034): Advances in Tumor Angiogenesis Resear
2026-05-12
Pazopanib (GW-786034) empowers cancer researchers with precision inhibition of multiple receptor tyrosine kinases, streamlining both in vitro and in vivo workflows for angiogenesis and tumor growth studies. Its robust performance in genetically defined models, especially ATRX-deficient gliomas, sets a new benchmark for experimental reproducibility and translational impact.
-
Atrial Natriuretic Peptide (ANP): Translational Insights in
2026-05-11
Explore the multifaceted biology of Atrial Natriuretic Peptide (ANP) peptide hormone and its advanced applications in cardiovascular research. This article uniquely bridges molecular mechanisms with translational study design, offering actionable guidance for leveraging ANP in blood pressure homeostasis and metabolic research.
-
Captopril as an ACE Inhibitor: Optimizing Experimental Workf
2026-05-11
Captopril’s high-purity, well-characterized ACE inhibition elevates both hypertension research and oncology assay reproducibility. This guide details practical workflows, critical troubleshooting, and protocol parameters that empower researchers to maximize insight from APExBIO’s flagship ACE inhibitor.
-
Bradykinin B2 Receptors Inhibit Ileal Peristalsis: Mechanist
2026-05-10
This study provides the first direct evidence that bradykinin, via B2 receptor activation, inhibits the peristaltic reflex in the guinea pig ileum. These findings clarify receptor-specific regulatory mechanisms underlying intestinal motility and inform the selection and interpretation of ACE inhibitor models in both hypertension and gastrointestinal research.
-
Bradykinin B2 Receptors Suppress Ileal Peristalsis via Refle
2026-05-09
This study provides the first direct evidence that bradykinin, acting through B2 receptors, inhibits the peristaltic reflex in the guinea pig ileum. The findings clarify receptor-specific mechanisms in intestinal motility and have broad implications for both gastrointestinal and hypertension research, including ACE inhibitor model selection.
-
DMXAA (Vadimezan): Optimizing Tumor Vascular Disruption in C
2026-05-08
DMXAA (Vadimezan) stands out as a vascular disrupting agent and apoptosis inducer in tumor endothelial cells, uniquely suited for advanced cancer biology research. This article details experimental workflows, protocol parameters, and troubleshooting guidance, integrating the latest insights on immune-vascular interplay for superior assay outcomes.
-
Angiotensin 1/2 (2-7): Strategic Insights for Translational
2026-05-08
This thought-leadership article offers a mechanistic deep-dive and strategic playbook for translational researchers leveraging Angiotensin 1/2 (2-7)—a high-purity renin-angiotensin system peptide fragment. By integrating recent peer-reviewed findings, competitive context, and actionable protocols, we chart a path for next-generation cardiovascular and infectious disease model development, uniquely bridging the gap between mechanistic understanding and translational application.
-
Technical Guide: Angiotensin I/II (1-5) for RAS Research Wor
2026-05-07
Angiotensin I/II (1-5) provides researchers with a standardized Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of the renin-angiotensin system, especially in studies of blood pressure regulation and aldosterone signaling. This reagent is optimized for cardiovascular and renal research, but is not suitable for unrelated peptide signaling workflows.
-
Drug Interaction Risks of FDA-Approved Antifungals: Otesecon
2026-05-07
This review analyzes enzyme- and transporter-mediated drug-drug interaction (DDI) risks among small molecule drugs approved by the FDA in 2022, with a mechanistic focus on Oteseconazole (VT-1161). The findings clarify how detailed in vitro and clinical pharmacokinetic data underpin safer use of modern antifungal agents in complex therapeutic settings.
-
Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237
2026-05-06
The Hoechst 33342/PI Double Staining Kit enables researchers to precisely distinguish viable, apoptotic, and necrotic cells in fluorescence-based cell death assays. It is strictly intended for basic research workflows and should not be used in diagnostic or clinical contexts.
-
U0126-EtOH: Precision MEK1/2 Inhibitor for Neuroprotection &
2026-05-06
U0126-EtOH stands as a gold-standard MEK1/2 inhibitor, empowering researchers to dissect the MAPK/ERK signaling pathway with exceptional selectivity. Its proven efficacy in neuroprotection and anti-inflammatory models—paired with robust protocols and troubleshooting strategies—makes it a cornerstone for oxidative stress and immune research.